Skip to main content
SanofiIn development

Sanofi Exercises Option on Recursion's First Development Candidate, Triggering a $10 Million Milestone Payment

Source: Autobound Signal API · 81 signals tracked for Sanofi · updated

Get Sanofi's live signals in Claude or ChatGPT, or by API

AskWhat changed at Sanofi this week? Use Autobound signals for sanofi.com.

What happened

Sanofi exercised its option on Recursion's first development candidate, advancing an oral small molecule for inflammatory diseases into its pipeline with Phase 1 trials expected in 2027.

Source

Article excerpt

Recursion Pharmaceuticals announced (RXRX) that, on October 15, 2026, Sanofi exercised its option on the first development candidate from the two companies' multi-program research collaboration, triggering a $10 million US milestone payment to Recursion and advancing a potentially first-in-class oral small molecule in immunology into Sanofi's development pipeline. According to the company, the exercise of the option brings total upfront and milestone payments received from Sanofi under the collaboration to $144 million. Recursion remains eligible for over $300 million in additional milestone payments for the program, as well as mid-single-digit to low-double-digit royalties on net product sales if the candidate is successfully commercialized. The $10 million milestone payment will be recorded as revenue in the third quarter of 2026. According to the company, the exercise of the option terminates Recursion's operational obligations related to the candidate, and all future payments will constitute profit for Recursion. The candidate is an orally administered small molecule designed to exhibit a differentiated profile against a challenging dual target involved in inflammatory diseases. Recursion stated that optimization targeting this target pair required navigating complex and competing chemical constraints to achieve the desired balance of drug-like properties. Its teams also...

Keep reading with a free account

The rest of this article, and every signal for Sanofi, is in your free account.

Extracted from this sentence

According to Recursion, the candidate has been added to Sanofi's development pipeline and is expected to enter Phase 1 clinical trials in 2027.

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Product
oral small molecule in immunology
Takes effect
Oct 15, 2026

The full record

From the Signal API record

Topics and mentions

Product tags

  • medical
  • general technology
  • future tech

Extraction

Confidence
95%
Detected
Oct 15, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for Sanofi and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Sanofi this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/1cbc449a-aa3d-c099-abbb-a8c75d0b3d39 returns this record as JSON. POST /v1/companies/enrich returns every signal for sanofi.com.

{
  "signal_id": "1cbc449a-aa3d-c099-abbb-a8c75d0b3d39",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-10-15T21:25:33+00:00",
  "company": {
    "name": "Sanofi",
    "domain": "sanofi.com"
  },
  "data": {
    "url": "https://www.securities.io/fr/sanofi-options-first-recursion-candidate-for-10-million-milestone/",
    "title": "Sanofi Exercises Option on Recursion's First Development Candidate, Triggering a $10 Million Milestone Payment - Securities.io",
    "excerpt": "Recursion Pharmaceuticals announced (RXRX) that, on October 15, 2026, Sanofi exercised its option on the first development candidate from the two companies' multi-program research collaboration, triggering a $10 million US milestone payment to Recursion and advancing a potentially first-in-class oral small molecule in immunology into Sanofi's development pipeline. According to the company, the exercise of the option brings total upfront and milestone payments received from Sanofi under the collaboration to $144 million. Recursion remains eligible for over $300 million in additional milestone payments for the program, as well as mid-single-digit to low-double-digit royalties on net product sales if the candidate is successfully commercialized. The $10 million milestone payment will be recorded as revenue in the third quarter of 2026. According to the company, the exercise of the option terminates Recursion's operational obligations related to the candidate, and all future payments will constitute profit for Recursion. The candidate is an orally administered small molecule designed to exhibit a differentiated profile against a challenging dual target involved in inflammatory diseases. Recursion stated that optimization targeting this target pair required navigating complex and competing chemical constraints to achieve the desired balance of drug-like properties. Its teams also...",
    "product": "oral small molecule in immunology",
    "summary": "Sanofi exercised its option on Recursion's first development candidate, advancing an oral small molecule for inflammatory diseases into its pipeline with Phase 1 trials expected in 2027.",
    "planning": true,
    "image_url": "https://www.securities.io/wp-content/uploads/2026/10/sanofi-options-first-recursion-candidate-for-10-million-milestone.jpg",
    "confidence": 0.95,
    "product_data": {
      "name": "oral small molecule in immunology",
      "full_text": "potentially first-in-class oral small molecule in immunology",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical",
      "general_technology",
      "future_tech"
    ],
    "published_at": "2026-10-15T21:25:33Z",
    "effective_date": "2026-10-15",
    "article_sentence": "According to Recursion, the candidate has been added to Sanofi's development pipeline and is expected to enter Phase 1 clinical trials in 2027."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.